MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1093/oncolo/oyae087

Медицинская библиотека · The oncologist · 2024

Health-related quality-of-life analysis from KEYNOTE-590: pembrolizumab plus chemotherapy versus chemotherapy for advanced esophageal cancer.

Mansoor Wasat, Joo Seongjung, Norquist Josephine M, Kato Ken, Sun Jong-Mu, Shah Manish A, Enzinger Peter, Adenis Antoine, Doi Toshihiko, Kojima Takashi, Metges Jean-Philippe, Li Zhigang, Kim Sung-Bae, Cho Byoung Chol, Sunpaweravong Patrapim, Alsina Maria, Goekkurt Eray, Suryawanshi Shailaja, Shah Sukrut, Shen Lin

СтатьяРандомизированное исследованиеКлиническое исследование III фазыПоддержка исследования: вне правительства СШАПеревод в очереди

Аннотация

BACKGROUND

In the KEYNOTE-590 study, first-line pembrolizumab plus chemotherapy provided statistically significant improvement in overall survival, progression-free survival, and objective response rate compared with chemotherapy, with a manageable safety profile in patients with advanced esophageal cancer. Prespecified health-related quality-of-life (HRQoL) outcomes are reported.

MATERIALS AND

METHODS

Change from baseline to week 18 in the EORTC Quality of Life Questionnaire Core 30 (QLQ-C30) global health status/QoL (GHS/QoL) and QLQ-Esophageal cancer module (OES18) dysphagia, pain, and reflux scales were evaluated.

RESULTS

The HRQoL analysis included 730 patients who received treatment and completed ≥1 HRQoL assessment. Least squares mean (LSM) change from baseline to week 18 was similar between treatment groups for QLQ-C30 GHS/QoL and physical functioning and QLQ-OES18 reflux scales. The QLQ-OES18 dysphagia (LSM difference, -5.54; 95% CI, -10.93 to -0.16) and pain (LSM difference, -2.94; 95% CI, -5.86 to -0.02) scales favored pembrolizumab plus chemotherapy over placebo plus chemotherapy. Median time to confirmed deterioration (TTD) was similar between treatment groups for QLQ-C30 GHS/QoL and physical functioning and QLQ-OES18 dysphagia and reflux scales. Compared with chemotherapy, pembrolizumab plus chemotherapy prolonged median TTD, as seen on the QLQ-OES18 pain scale (HR, 0.69; 95% CI, 0.51 to 0.95).

CONCLUSION

The use of pembrolizumab plus chemotherapy maintained HRQoL at week 18 relative to baseline and was comparable with placebo plus chemotherapy. These HRQoL results together with published reports of efficacy, support the use of pembrolizumab plus chemotherapy as first-line therapy for advanced/metastatic esophageal cancer.

CLINICALTRIALS.GOV ID: NCT03189719.

Для цитирования: Mansoor Wasat, Joo Seongjung, Norquist Josephine M, Kato Ken, Sun Jong-Mu, Shah Manish A, Enzinger Peter, Adenis Antoine, Doi Toshihiko, Kojima Takashi, Metges Jean-Philippe, Li Zhigang, Kim Sung-Bae, Cho Byoung Chol, Sunpaweravong Patrapim, Alsina Maria, Goekkurt Eray, Suryawanshi Shailaja, Shah Sukrut, Shen Lin. Health-related quality-of-life analysis from KEYNOTE-590: pembrolizumab plus chemotherapy versus chemotherapy for advanced esophageal cancer.. The oncologist. 2024. DOI: 10.1093/oncolo/oyae087.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.